X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Pharma Trade Group Sues Biden Admin Over Medicare Drug Costs

Content Team by Content Team
28th June 2023
in FDA Approvals, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

On June 21, the pharma sector’s biggest lobbying group, along with two major organisations, went on to sue the Biden administration when it came to the new powers of Medicare to cut medicine prices for seniors as per the Inflation Reduction Act.

Pharma Research and Manufacturers of America, as well as the Global Colon Cancer Association and the National Infusion Centre Association, go on to argue that the Medicare negotiations with the drugmakers violate the constitution of the US, and they have thereby filed a complaint with the federal district court in Texas.

It is well to be noted that PhRMA happens to represent numerous of the largest drugmakers across the world, including the likes of Pfizer, Johnson & Johnson, and Eli Lilly. The groups went on to ask the courts to go ahead and declare the programme unconstitutional and also safeguard the department of health and human services from executing Medicare negotiations sans ample procedural precautions in the case of drug manufacturers.

This marks the fourth lawsuit filed challenging the controversial provision when it comes to the Inflation Reduction Act, which apparently became law last summer in a prominent victory for President Biden as well as the Democratic lawmakers.

The policy looks to make the medicines more affordable when it comes to senior Americans; however, it is likely to cause a dip in the pharma sector’s profits. Merck as well as Bristol-Myers Squibb, which is also represented by the US Chamber of Commerce and PhRMA, filed individual lawsuits against this provision earlier in June.

The recent lawsuit goes on to argue that this plan delegates too much authority to HHS. PhRMA as well as the two pharma giants also put forth the fact that this provision has in it a crippling excise tax that is aimed at compelling the drugmakers to carry out the government-dictated price of drugs, thereby making it an additional fine prohibited by the Eighth Amendment.

The lawsuit also goes on to argue that the policy does violate due process by denying pharma companies as well as public input on how the Medicare negotiations can go on to get executed. As per Stephen Ubl, the CEO of PhRMA, the price-setting scheme within the IRA happens to be a bad policy that threatens continued research and development as well as patients’ access to drugs. He added the scheme also violates the US Constitution since it has in it barriers to ownership as well as transparency, hands over to the executive branch unfettered discretion when it comes to setting the rate of medicines in Medicare, and also relies heavily on an illogical enforcement mechanism so as to push compliance.

Apparently, the first 10 medicines where this provision is going to be applied will be chosen in September, and the agreed prices are going to come into effect in 2026.

Previous Post

Adapting Digital Transformation In The Life Sciences Sector

Next Post

Pharma May Lose Out To Competition Due To EU Health Package

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Pharma May Lose Out To Competition Due To EU Health Package

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In